Dr Feigal serves as a board member for Xencor Inc, a biotechnology company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases. She is also a director of NextCure, a clinical-stage biotechnology company developing new immunotherapies to treat cancer. "Critical phase" "I am excited to join the board of Prescient at this critical phase in the company's journey," Dr Feigal said.